Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Last updated: May 3, 2024
Sponsor: University of Arizona
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scalp Disorders

Hair Loss

Alopecia

Treatment

LaserCap HD+

LaserCap SD

Sham LaserCap

Clinical Study ID

NCT05365360
LLLT Fluence RCT
  • Ages > 25
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1.

In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the ~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3.

Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • 25 years and older
  • Men and women with AGA, untreated or with 6-month washout of previous treatments
  • Men: Norwood stage IIa - V
  • Women: Ludwig I-1 - II-2, or frontal pattern
  • All patients: Fitzpatrick skin types I to IV

Exclusion

Exclusion criteria:

  • Men: Norwood stage Va, VI, VII
  • Women: Ludwig stage III, advanced
  • All patients: Fitzpatrick skin types V, VI
  • Current use or within the past six month of other treatment for AGA, including topicaland oral minoxidil, topical and oral finasteride and dutasteride
  • Age 0-25 years

Study Design

Total Participants: 50
Treatment Group(s): 3
Primary Treatment: LaserCap HD+
Phase:
Study Start date:
June 01, 2022
Estimated Completion Date:
May 31, 2025

Connect with a study center

  • Banner University Dermatology

    Tucson, Arizona 85719
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.